Document is current
Any future updates will be listed below
-
Authors
Landsburg, Daniel J. https://orcid.org/0000-0002-5077-4181
Musoke, Nancy https://orcid.org/0000-0003-4690-7516
Gentile, Caren https://orcid.org/0000-0002-3997-5249
Brooks, Taylor R.
Nasta, Sunita D.
Barta, Stefan K. https://orcid.org/0000-0002-3280-5271
Carter, Jordan S.
Chong, Elise A. https://orcid.org/0000-0001-8895-1625
Svoboda, Jakub
Schuster, Stephen J.
Thomas, Colin J.
Tomasulo, Emily B. https://orcid.org/0000-0003-3030-8738
Cook, Michael R.
Morrissette, Jennifer J. D.
Caimi, Paolo F.
Hill, Brian T.
- License Information
-
More Information
Article History
Received: 2 September 2025
Revised: 9 December 2025
Accepted: 27 January 2026
First Online: 17 February 2026
Competing interests
: DJL Genentech/Roche: Consultancy; ADC Therapeutics: Consultancy, Research Funding; AbbVie: Consultancy; Novartis: Consultancy, Research Funding; Kite: Consultancy; Ipsen: Consultancy. NM none. CG none. TRB none. SDN: Pierre Fabre: Consultancy; Caribou: Research Funding; Takeda: Research Funding; Roche: Research Funding; ONO Therapeutics: Research Funding; Merck: Consultancy; GenMab: Honoraria; Loxo/Lilly: Research Funding; AbbVie: Honoraria; ATARA: Research Funding; Pharmacyclics: Research Funding. SKB Daiichi Sankyo: Consultancy, Research Funding; Citius: Consulting; Bioinvent: Research Funding; Secura Bio: Consulting; Janssen: Honoraria; Affimed: Consultancy, Research Funding; Kymera: Research Funding; Vittoria Biotherapeutics: Research Funding; Kyowa Kirin: Consultancy, Research Funding; Honoraria; ONO: Consultancy, Research Funding; Acrotech: Consultancy, Research Funding, Honoraria. JSC none. EAC Nurix: Research Funding; CARGO: Research Funding; Genentech: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; Genmab: Consultancy, Research Funding. JS Genmab: Consultancy, Honoraria. SJS Acerta: Consultancy; Novartis: Consultancy, Research Funding; Nordic Nanovcector: Consultancy; Genentech: Consultancy; Celgene: Consultancy, Research Funding; Gilead: Research Funding; Merck: Research Funding; Pharmacyclics: Consultancy, Research Funding; Janssen: Research Funding. CJT: Reckner: Honoraria; Acrotech: Consultancy; Electra Therapeutics: Consultancy. EBT none. MRC none. JJDM none. P.C. AbbVie: Consultancy, Research Funding; Genmab: Consultancy, Research Funding; Recordati: Research Funding; ADC Therapeutics: Consultancy; Autolous: Consultancy; Bristol Myers Squibb: Consultancy; Genentech: Consultancy; Novartis: Consultancy. BTH: Abbvie: Consultancy, Research Funding, Honoraria; AstraZeneca: Consultancy, Honoraria; Bayer: Honoraria; Beigene: Consultancy, Honoraria; Celgene: Honoraria, Research Funding; Epizyme: Consultancy, Honoraria; Genentech: Consultancy, Research Funding, Honoraria; Gilead Sciences: Consultancy, Honoraria; Karyopharm Therapeutics: Consultancy, Research Funding, Honoraria; Morphosys: Consultancy, Research Funding, Honoraria; Novartis: Consultancy, Research Funding, Honoraria; Pfizer: Honoraria; Pharmacyclics: Honoraria; Takeda: Research Funding; TG Therapeutics: Research Funding.
